Podcasts about eular

What happens at one of the world's largest rheumatology conferences, and why should patients care? In this special episode of The Health Advocates, Steven Newmark is joined by Dr. Shilpa Venkatachalam, Director of Patient-Centered Research at the Global Healthy Living Foundation (GHLF), to discuss the biggest takeaways from EULAR 2026, the annual congress of the European Alliance of Associations for Rheumatology. The conversation explores why conferences like EULAR are so important for advancing patient care, how researchers, physicians, and patient advocates work together to shape the future of rheumatology, and why the patient voice has become an essential part of medical research. Steven and Shilpa also highlight GHLF's contributions to this year's conference, including two original research posters examining barriers to the early recognition of hidradenitis suppurativa and the unmet informational and support needs of people living with Sjögren's disease. Along the way, they discuss exciting emerging trends in rheumatology and clinical care, especially the increasing emphasis on patient-reported outcomes. Whether you're living with a rheumatic disease, caring for someone who is, or simply interested in the future of healthcare, this episode offers an inside look at how today's research is helping shape tomorrow's treatments—and why patient perspectives are more important than ever. Access the GHLF HS Diagnosis Accelerator: https://ghlf.org/hscheck/ Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Amelia Violet Prouse, Associate Podcast & Video Producer at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology's most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.

Join Professors Xenofon Baraliakos, Laura Coates and Dr Sofia Ramiro as they break down the top RA, PsA and axSpA abstracts, sessions and posters from this year's EULAR conference.

Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping RA practice right now.

Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know. Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.

What actually happens at a major international medical conference — and why should patients care? In this episode of The Health Advocates, Steven Newmark reports from EULAR 2026 in London, one of the world’s largest rheumatology conferences, to explain how meetings like this help shape the future of patient care. The episode explores why conferences matter not just for doctors and researchers, but for patients and advocacy organizations as well. Steven discusses how practicing clinicians learn about the latest medical advances, how researchers connect directly with physicians treating patients every day, and why organizations like GHLF play an important role in bringing real-world patient experiences into scientific and medical conversations. The episode also highlights several emerging themes already generating excitement at EULAR this year, including the growing role of artificial intelligence in rheumatology and the potential future of CAR-T and cell therapies for autoimmune diseases like lupus and rheumatoid arthritis. Most importantly, the conversation explains how scientific innovation ultimately connects back to what matters most: improving the daily lives of patients. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Amelia Violet Prouse, Associate Podcast & Video Producer at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel. See omnystudio.com/listener for privacy information.

Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis" Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA How Many CAR-Ts Do We Need to Test Drive? Making Methotrexate More Effective

Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Day 4 of the EULAR 2026 Congress. Abstracts discussed included: LB001 LB002 LB003 LB005 LB007 LB009 RA Plenary POS1350

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 4 of EULAR 2026 (Saturday, June 6th).

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 3 of the EULAR 2026 Congress. Abstracts discussed included: OP0348  POS0290  OP0342  POS1068  POS0201  POS0288

BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs

Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA Digital Patient Education in RA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis  

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Can We Stop PsA Before it Starts? Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 3 of EULAR 2026 (Friday, June 5th).

Join Dr. Jack Cush and RheumNow.com faculty for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 1 & 2 of the EULAR 2026 Congress. Abstracts discussed included: OP0177 OP0244   OP001 OP008 OP0205  OP018 OP0204 POS0788

Imaging in Subclinical Psoriatic Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman's World: Women's Health in Rheumatic Disease Dietary Interventions in PsA

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 2 of EULAR 2026 (Thursday, June 4th).

2026 EULAR Preview - Dr. Jack Cush ‘Strong' Treatment Predictions in Inflammatory Myositis - Dr. Janet Pope Beyond BMI: Altered Body Composition in Rheumatoid Arthritis - Dr Mrinalini Dey Why PROMS Matter in the Care of People with Lupus - Dr. Mrinalini Dey

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 1 of EULAR 2026 (Wednesday, June 3rd).

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including:  Obesity, Weight Management, and Psoriatic Arthritis Sessions Personalized Medicine and Biomarkers in RMDs Sessions Fatigue and Quality of Life in Connective Tissue Disease Session Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session Artificial Intelligence and Pattern Recognition in Rheumatology Sessions Axial Imaging in Axial Spondyloarthritis Session Head-to-Head Superiority Trials in RA and PsA Sessions CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions

Join Professor Xenofon Baraliakos as he guides you through what we are most looking forward to in RA, PsA, and axSpA at EULAR 2026, so that you can better plan your time at what will be a busy and exciting congress

W tym odcinku podcastu omawiam nowe rekomendacje EULAR 2025, które pokazują, że aktywność fizyczna nie jest dodatkiem do leczenia chorób zapalnych stawów i choroby zwyrodnieniowej - tylko jego ważną częścią. Dr Tomasz Chomiuk – absolwent fizjoterapii AWF i WUM, doktor nauk medycznych, specjalista fizjoterapii, adiunkt w III Klinice Chorób Wewnętrznych i Kardiologii Wydziału Lekarskiego WUM, współtwórca Polskiego Towarzystwa Medycyny Długowieczności oraz członek Sekcji Kardiologii Sportowej Polskiego Towarzystwa Kardiologicznego. Współtwórca prywatnej placówki medycznej Mobilemed świadczącej mobilne usługi fizjoterapeutyczne na terenie całej Polski. Propagator aktywności fizycznej jako metody profilaktyki i leczenia. W odcinku usłyszysz między innymi o:  dlaczego „oszczędzanie stawów” bywa pułapką i co mówi EULAR 2025  tym, że liczy się nie tylko trening, ale też ograniczanie siedzenia  „exercise snacks” – czyli krótkich „przekąskach ruchowych”  czterech filarach aktywności: wydolność, siła, elastyczność, równowaga/koordynacja  praktycznej „regule 24 godzin” - kiedy zmniejszyć obciążenie po ćwiczeniach  dawkowaniu ruchu jak leku (FITT-VP)  monitorowaniu efektów (także technologią) Link do artykułu:

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they will review a paper by Smolen et al. provides an update of the EULAR RA management recommendations addressing the most recent insights; and by Narváez et al. developed evidence-informed, profile-based recommendations to guide treatment selection after inadequate response to a first TNFi in RA, combining evidence and expert consensus.

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Helena Marzo-Ortega an academic clinician and the Clinical Lead of the multi-award winning Leeds Specialist Spondyloarthropathy service at The Leeds Teaching Hospitals NHS Trust, as they discuss her recent paper ‘EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis'.

Remission is no longer an abstract idea for people living with AiArthritis diseases. Thanks to earlier diagnosis, better treatment options, and growing global awareness, more patients are reaching remission and staying there. In this episode of AiArthritis Voices 360, Health Education Manager Leila P. L. Valete sits down with Neil Betteridge of the Global Remission Coalition to explore what remission truly means and why it is becoming a realistic goal for many. Together they unpack how remission differs from basic disease control and why that distinction is so important for daily life. They also talk through the emotional and practical impact of reaching remission, the role of early action, and the barriers that still prevent many patients from accessing timely care. The conversation highlights what sustainable remission looks like in the real world and how better education, support, and policy attention can help more people get there. Whether you are newly diagnosed or years into your patient journey, this episode offers a grounded and hopeful look at the road to remission and the steps that can make a life-changing difference.   Episode Highlights: What remission really means and how it differs from basic disease control Why remission improves quality of life, mental health, and daily function Key factors that help patients reach remission including early diagnosis and timely treatment Common barriers patients face like limited access to specialists, treatment delays, and lack of information What it takes to sustain remission through monitoring, adherence, and patient support   Links & Resources Global Remissions resources: www.globalremission.org AiArthritis remission information: https://www.aiarthritis.org/remission Have questions about this episode or topics you want to hear us bring to the table? Email us at podcast@aiarthritis.org  Donate to Support the Show: www.aiarthritis.org/donate   Follow AiArthritis on all social media platforms @IFAiArthritis Sign up for our Monthly AiArthritis Voices 360 Talk Show newsletter! HERE   Connect with our Co Hosts: Leila is the Health Education Manager at the International Foundation for AiArthritis. She is a person living with Lupus and Sjögren's disease. She is passionate about inclusion and diversity in health education and meeting individuals where they are at in order to learn in a way that resonates with them.  Connect with Leila: Tiktok: @Lupuslifestyle.lei   Neil Betteridge developed juvenile arthritis at age three, an experience that shaped his lifelong commitment to advocating for people with chronic diseases. He has led major patient organizations in the UK and globally, including serving as CEO of Arthritis Care and now as Senior Director of the Global Alliance for Patient Access, where he also chairs the Global Remission Coalition. With decades of experience in public affairs and patient engagement, Neil has advised health ministers, worked with the Royal College of Physicians, and held key leadership roles in international networks such as the Global Alliance for Musculoskeletal Health and EULAR. His work continues to advance policy, access, and better outcomes for people living with chronic inflammatory conditions. Connect with Neil: Website: www.globalremission.org X/Twitter: https://x.com/Neil_Betteridge

Cannabis has come a long way since we last covered it in 2020. With more patients using CBD and medical cannabis to help manage chronic pain, inflammation, anxiety, and sleep issues, it is time for an important update. In this episode, AiArthritis Health Education Manager Leila P. L. Valete is joined by co-hosts and patient advocates Eileen Davidson and Bridget Seritt for a real conversation about what has changed, what we still need to learn, and what patients should know before trying cannabis for autoimmune and autoinflammatory arthritis. The hosts explore how research, attitudes, and medical discussions around cannabis have evolved. They share their own experiences using CBD and cannabis, discuss new findings from rheumatology research, and highlight the ongoing need for better access, safety education, and provider awareness. The conversation also looks at how stigma is shifting as more patients and clinicians see cannabis as a legitimate part of symptom management rather than a last resort. Whether you're new to the topic or already using cannabis as part of your treatment, this episode offers clear guidance, personal insight, and a thoughtful look at its role in patient care.   Episode Highlights: How conversations around cannabis and CBD have evolved since 2020 What new research says about its role in managing pain, sleep, and mental health Patient experiences using cannabis alongside traditional treatments Benefits, risks, and the ongoing debate around medical versus self-directed use How access, education, and stigma continue to shape patient choices   Links & Resources Go With Us! to EULAR 2025: Should Doctors Prescribe Cannabis for Autoimmune Disease?: https://www.youtube.com/watch?v=iw-KJWbKpuo Have questions about this episode or topics you want to hear us bring to the table? Email us at podcast@aiarthritis.org  Donate to Support the Show: www.aiarthritis.org/donate   Follow AiArthritis on all social media platforms @IFAiArthritis Sign up for our Monthly AiArthritis Voices 360 Talk Show newsletter! HERE   Connect with our Co Hosts: Leila is the Health Education Manager at the International Foundation for AiArthritis. She is a person living with Lupus and Sjögren's disease. She is passionate about inclusion and diversity in health education and meeting individuals where they are at in order to learn in a way that resonates with them.    Connect with Leila: Tiktok: @Lupus.lifestyle.lei Instagram: @Lupus.lifestyle.lei   Eileen Davidson is a rheumatoid arthritis patient advocate from Vancouver Canada. She volunteers with the Arthritis Research Canada patient advisory board and the Canadian Institute of Health Research - Institute of Musculoskeletal Health and Arthritis patient engagement research ambassador, among others. When not advocating she is writing about her experience with arthritis through Creaky Joints, Healthline, Chronic Eileen or can be found being a mom to her son Jacob.   Connect with Eileen: Twitter: @ChronicEileen Instagram: @ChronicEileen Facebook: @ChronicEileen   Bridget Dandaraw-Seritt founded a patient based organization that advocates for access to compassionate care and provides community support. She's a published author on therapeutic cannabis, presents at medical conferences, and is engaged in the policy making process. Connect with Bridget: Facebook: Advocates for Compassionate Therapy Now   

This webinar will review the ACR and EULAR guidelines on interstitial lung disease, with a focus on ‘where are we now and where are we going?' in regards to treatment strategies and emerging therapies in ILD care. Panelists: Sindhu Johnson, MD Shane Shapera, MD Scott Matson, MD Jack Cush, MD - Moderator https://youtube.com/live/Viexwyv0sxs?feature=share

In this follow-up episode, AiArthritis Health Education Manager Leila reflects on her personal pregnancy journey with lupus and Sjögren's, while sharing key fertility and pregnancy insights from EULAR 2024. She highlights emerging research and clinical recommendations on preconception planning, navigating medication decisions, and coordinating care between rheumatologists and high-risk OB-GYNs. Leila also offers practical tips based on her own experience from managing disease activity during pregnancy to advocating for your needs throughout the journey. Join us on this episode if you're actively planning for a family or simply want to understand how AiArthritis diseases can impact fertility and pregnancy.    Donate to Support the Show: www.aiarthritis.org/donate   Episode Highlights: Hear EULAR 2024 updates on fertility and pregnancy Learn what current guidelines say about safe medications for conception, pregnancy, and breastfeeding Understand the importance of low disease activity before and during pregnancy Hear Leila's firsthand story of managing pregnancy with lupus and Sjögren's Discover why early conversations with rheumatologists matter even if you're not trying to conceive yet Explore the emotional and mental health side of pregnancy with chronic illness Get tips for building a supportive care team including maternal-fetal medicine specialists   Links & Resources Have questions about this episode or topics you want to hear us bring to the table? Email us at podcast@aiarthritis.org  Follow AiArthritis on all social media platforms @IFAiArthritis Sign up for our Monthly AiArthritis Voices 360 Talk Show newsletter! HERE   Connect with our Co Hosts: Leila is the Health Education Manager at the International Foundation for AiArthritis. She is a person living with Lupus and Sjögren's disease. She is passionate about inclusion and diversity in health education and meeting individuals where they are at in order to learn in a way that resonates with them.

Join rheumatology experts Dr. John J. Cush and Dr. Arthur Kavanaugh for the EULAR Rheumatology RoundUp — a dynamic, fast-paced discussion capturing the most impactful highlights, late-breaking data, and clinical takeaways from EULAR 2025.

Trends and Innovations from Barcelona (6.20.2025) AI Advances axSpA Diagnosis with Multimodal MRI IL-17 Inhibitors in Psoriatic Arthritis IL-17 Inhibitors for Axial Spondyloarthritis New IL-17 Inhibition New Molecular Constructs

Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life Spondyloarthritis Panel: Eular 2025

Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what's new from EULAR 2025 and what it means for improving patient outcomes.

Digital Behavioural Therapy for Persistent Pain in Axial Spondyloarthritis There's an App for That (and it works): the AXIA RCT

Eular 2025 PsA Topic Panel Assessment of Peripheral Arthritis in Spondyloarthritis IL-17 inhibitors - Novel Drugs IL17 inhibitors - Long-term Extensions and Uveitis IL17 inhibitors - STAMP T2T and Combinations Using AI for Reading PET/CT in Rheumatoid Arthritis

Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don't miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what's next for RA care.

EULAR 2025 - Day 1 podcasts Sonelokimab in PsA Seronegative Arthritis Breakthroughs Using Combination csDMARDs in PsA Deucravacitinib's Place in the PsA Treatment Algorithm?

Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact GLP 1 Receptor Agonists in axSpA Patients Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral All Rheumatoid Arthritis is Not the Same

Deucravacitinib's Place in the PsA Treatment Algorithm? Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIPPRA

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.  

Seronegative Arthritis Breakthroughs Jokes Aside: The Impact of Laughter in RA The Impact of Biologics on Methotrexate Adherence Thoughtful, Effective RA Care Should be Guided by Need —Not Age Sonelokimab in PsA Using Combination csDMARDs in PsA

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.  

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the first day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

Efficacy and Safety of Xeligekimab in AS Who/When to Treat Clinically Suspect Arthralgia